Haichang Biopharmaceutical Technology

Based in Hangzhou, China, the company operates as a research-driven enterprise, integrating R&D with production and sales. Its business model centers on developing a pipeline of pharmaceutical products and leveraging its proprietary drug delivery technology platforms: QTsome®, PEGsome, and DEPOsome. The company's product pipeline covers multiple therapeutic areas, including anti-tumor therapy, tumor immunotherapy, analgesia, and infectious disease prevention. Key products in development include HC0301, a small nucleic acid drug for primary liver cancer; HC016, a TLR9 agonist for solid tumors; and HC009, an mRNA vaccine for COVID-19. Additionally, the company develops complex generic injections, such as a version of Abraxane® for various cancers.

Haichang Biopharmaceutical Technology generates revenue through the commercialization of its products and strategic partnerships. For example, its paclitaxel (albumin-bound) product has been approved for sale in nearly 40 countries, including in the European Union. The company has also entered into regional partnerships, such as with Dr. Reddy's Laboratories for its HC007 product in the U.S. It has secured funding from multiple investors through various financing rounds, including a Series B round in late 2021.